EN | UA
EN | UA

Help Support

Back

Romosozumab, a dual action drug found effective in osteoporosis management

Romosozumab, a dual action drug found effective in osteoporosis management Romosozumab, a dual action drug found effective in osteoporosis management
Romosozumab, a dual action drug found effective in osteoporosis management Romosozumab, a dual action drug found effective in osteoporosis management

What's new?

Due to dual action on stimulating bone formation and reducing bone resorption, Romosozumab decreases the risk of both vertebral and non vertebral fractures in osteoporosis patients.

As per a recent study of the British Journal of Clinical Pharmacology, Teriparatide, Abaloparatide and Romosozumab are the new anabolic therapies for osteoporosis management. Abaloparatide (ABL) and Teriparatide (TPTD) are previously available therapies, and Romosozumab is under the examination.

The ABL is an analogue of the parathyroid hormone-related peptide (PTHrP) with considerably different amino acids included between residues 22 and 34. The TPTD is a recombinant 34–amino acid fragment that shows similar principal sequence as the human parathyroid hormone [hPTH(1‐84)].

Parathyroid hormone (PTH) shows osteoanabolic actions directly by affecting osteoblast lineage cells and indirectly by prompting IGF‐I synthesis and inhibiting sclerostin and related improvement of Wnt signalling. Both ABL and TPTD binds and stimulate the PTH receptor type 1 (PTHR1) receptor, though they seem to do so differently. ABL supports the transient, more anabolic arrangement of the receptor. The risk of non-vertebral fractures and vertebral fractures was reduced by both ABL and TPTD. Both drugs are delivered maximum for 24 months and should be succeeded by an anti‐resorptive agent to control increase in BMD.

Romosozumab is a monoclonal antibody which shows its action by binding and suppressing sclerostin. It is associated with a rapid but very transient increase in bone formation markers. In the pivotal clinical analysis, Romosozumab 210 mg delivered subcutaneously decreases fracture risk but it is not clear whether it is associated with an increase in serious cardiovascular adverse effects.

 

Source:

Br J Clin Pharmacol.

Article:

Osteoanabolic and Dual Action Drugs.

Authors:

Gaia Tabacco, John P. Bilezikian

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: